Angels Among Us - Team Friedman's Fighters

Hi Family and Friends,

Just a quick note to let you know that we are set to participate in our 4th annual Angels Among Us 5K Run/Walk on Saturday April 26th, 2019 at the Duke Medical Center in Durham, NC.  Our team name is once again Friedman's Fighters in honor of Shawn's amazing surgeon, Dr. Allan Friedman, for whom we will be forever grateful!  We are hoping to raise funds for the Preston Robert Tisch Brain Tumor Center via Angels Among Us.  This the largest source of unrestricted funds and most critical for the research and development of advances in brain tumor treatment.  

Feel free to read below for a quick update on Shawn and Click on the Donate Link if you are so inclined - please do not feel pressured - we know there are many great causes - this one just happens to be near and dear to our hearts (and brains:).

 

Shawn Update 2/2019:

Shawn has been feeling great busy with work, kids activities and all of life's crazy normalcy thank goodness.  MRI's are every 4 months alternating between Duke and Emory.  Last scan at Emory in Dec was stable and the next one is in April at Duke right before the walk. We are lucky to have found Duke and grateful to be able to participate in this amaxing event once again.

 

Shawn Update 3/2017:

Aside from 2 minor bumps in the road in the form of grand mal seizures (one in March and one in May -at Torrey Pines of all places), Shawn has been doing awesome with stable MRIs every 8 weeks alternating visits between Duke and Emory.  We know we are lucky and just pray for Shawn's positive attitude and STABLE scans to continue!    Latest MRI on 3/8/17 at Duke was STABLE!

 

Shawn Update 3/2016:

As most of you know, Shawn was diagnosed with a brain tumor in October of 2014.  After initially being told that the tumor "looked" benign, we decided to go ahead and have surgery to remove it on Oct. 28th at Emory.  Unfortunately, not only was the tumor not benign, but because of it's location and the risk-tolerance level of the surgeon, only a small portion was removed.  A week later pathology confirmed our fears and it was determined to be an anaplastic astrocytoma -grade III.  Although this was not the news we were expecting or ever wanted to hear, it forced us to do more research and to seek 2nd, 3rd, and 4th opinions.  We were told that Shawn would have the best prognosis if the entire tumor was removed prior to starting radiation and chemo.   We ultimately decided on Duke based on their state of the art Brain Tumor Research Center, and most importantly, the experience of our surgeon, Dr. Allan Friedman and his confidence that the tumor could be removed without permanently altering his quality of life.  On Dec. 29th, the tumor was removed in it's entirety in less than 2 hours and with ZERO impact on shawn's vision and motor/sensory brain function.  He was released less than 24 hours later and able to celebrate New Years (2015) by watching college football with 2 good eyes:). Following this 2nd surgery, Shawn went through 6 weeks of radiation followed by a full year of monthly oral chemo (Temodar). As of March, he completed his 12th and hopefully FINAL round!!    Thankfully the MRIs have been stable after initially watching 2 very small spots which now appear to have been scar tissue.   He will continue to have MRIs every 8 weeks at Duke medical center.  Latest MRI on Mar. 15th was good/stable:):)

Thank you for the continued thoughts and prayers!!  XOXOXO

Whitney and Shawn

 

Why Give to The Robert Tisch Brain Tumor Center at Duke:

Public research funds are distributed based on the incidence of a given disease. Because brain cancer causes just two percent of all cancer deaths each year, it is officially classified as an “orphan disease” – a term that sums up its place in the eyes of federal funding agents.

Corporate sources are also limited. There are more than 120 identified types of brain malignancies, each with different chemical profiles and behaviors. Developing an effective new drug comes at a very high price. The market for such narrowly targeted drugs is simply too small for pharmaceutical companies to make big investments in clinical investigation.Why Give to The Robert Tisch Brain Tumor Center at Duke:

 

Event Sponsors